FDA Clears Gilead’s Regulatory Path For Three New Chemical Entities In HIV
This article was originally published in The Pink Sheet Daily
Executive Summary
Also waiting for agency word on its appeal to a “complete response” letter for aztreonam lysine in cystic fibrosis.
You may also be interested in...
Back To The Future: Gilead Signs Up Four Indian Companies To License Late-stage AIDS Therapies
MUMBAI - In a strategic step looking to protect intellectual property rights while ensuring access to affordable life-saving medicines in developing nations, anti-HIV drugs specialist Gilead Sciences Inc. struck licensing deals July 12 with four India-based drug manufacturers - Hetero Drugs Ltd., Ranbaxy Laboratories Ltd., Strides Arcolab Ltd., and Matrix Laboratories Ltd. - for three Gilead drugs that are in late-stage clinical development
Gilead/J&J Collaboration Seeks To Create Triple-Therapy Successor To Atripla
The opportunity for J&J's investigative non-nucleoside reverse transcriptase inhibitor may come at the expense of BMS, Gilead's partner on Atripla.
Gilead/J&J Collaboration Seeks To Create Triple-Therapy Successor To Atripla
The opportunity for J&J's investigative non-nucleoside reverse transcriptase inhibitor may come at the expense of BMS, Gilead's partner on Atripla.